Abstract
This research aims to evaluate the Type 2 Diabetes (T2D) diagnosis and prognosis power from heterogeneous environmental, lifestyle and biochemistry data. Model estimation has previously addressed three main actions as: 1) Missingvalue imputation using specific univariant and multivariant imputers accommodated to each particular feature; 2) Quasi-constancy detection in variables; 3) Constructing geographical pollution and rent data from municipality information. Next, different T2D diagnosis and prognosis models are fitted and evaluated, showing increasing performance as more specific features become available while the prediction cost rises as a consequence of requiring more specific data. Finally, four models are obtained: two of them for T2D diagnosis and the other two for T2D prognosis respectively, with performances ranging from 73.3 to 95.41 AUC-ROC. One pair of diagnosis and prognosis models were thought for a global testing that can be done in general locations by only asking general lifestyle-related questions. On the other hand, the other pair, which achieves higher performances, is thought to be applied in a clinical environment where it is easy to obtain more specific biochemistry measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The activities described in this document are part of the Cervera Network of Excellence in Data-Based Enabling Technologies (AI4ES) project, which is co-financed by the Center for Industrial Technological Development, E.P.E. (CDTI) and by the European Union through the Next Generation EU Fund, within the Cervera aid program for Technology Centers by the CDTI, with file number CER-20211030.
Research grants PI17/00544 and PI21/00506 from Ministerio de Ciencia e Innovación and Instituto de Salud Carlos III (ISCIII). CIBERDEM (CB07/08/0018) is part of CIBER (Consorcio Centro de Investigación Biomédica en Red) funded by ISCIII. Both research projects and CIBER are co-funded by the European Union (European Regional Development Fund (ERDF) “A way to build Europe”).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of Valencian Clinical Hospital gave ethical approval for this work (references 2017.184 and 2031/036).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email addresses: jonacer{at}iti.es (J.Ramón Navarro-Cerdán), pedropons{at}iti.es (Pedro Pons-Suñer), larnal{at}iti.es (Laura Arnal), arlandis{at}iti.es (Joaquim Arlandis), rllobet{at}iti.es (Rafael Llobet), jcperez{at}iti.es (Juan-Carlos Pérez-Cortés), a.barbara.garcia{at}ext.uv.es (Ana-Bárbara García-García), felipe.chaves{at}uv.es (Felipe Javier Chaves)
Data Availability
The dataset used in the present study is available upon reasonable request to the authors of the Di{at}bet.es Study.
